NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading
R&D and Clinical Programs
NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique
power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases
today announced that the company will be hosting an Investor/Analyst Day on January 8th in San Francisco.
NantKwest will be sharing with analysts and investors a review of the company’s activities in 2016 and provide an overview for
2017.
At this event, senior management of NantKwest will provide a review of its ongoing R&D program, as well as provide an
in-depth clinical trial roadmap for the aNK, haNK and taNK clinical programs for 2017.
In addition to senior management presentations, the event will feature presentations by key opinion leaders in the immunotherapy
field.
A webcast of the event will begin at 5:00 PM PT on Sunday, January 8, 2017 and is expected to conclude at 7:30 PT. A link to the
live webcast can be accessed by visiting the Investors page of the company's website. In addition, a replay of the event will be
posted on the website after the event and will be available for 30 days following the event.
About NantKwest
NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique
power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells
are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such
as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has
been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using
activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated
killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody,
enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells
engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer
cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell therapies including the reduction of risk of serious
"cytokine storms" reported after T cell therapy. As an “off-the-shelf” therapy, NantKwest's NK cells do not rely on a patient’s own
often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest's NK cells have been
successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion
cells.
By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that include a Phase 2 trial for a rare form of melanoma and the
planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies
to routine clinical care. For more information, please visit www.nantkwest.com.
NantKwest
Media Contact:
Jen Hodson, Public Relations Director
Cell, 562-397-3639
jhodson@nantworks.com
or
Investor Contact:
David Pyrce, SVP, Innovation and Chief Commercial Officer
Cell, 951-551-0949
david.pyrce@nantkwest.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161219005422/en/